Insider Transactions Reported by 9 Insiders of BELITE BIO, INC

Symbol
BLTE on Nasdaq
Location
San Diego, CA

There are no Buy or Sell transactions made by insiders since 18 Mar 2025

BELITE BIO, INC executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Hao-Yuan Chuang Chief Financial Officer, Director $36,817,027 18 Mar 2026
Yu-Hsin Lin Chief Executive Officer, Director $32,609,533 18 Mar 2026
Hendrik Peter Scholl Chief Medical Officer $6,599,250 18 Mar 2026
Wan-Shan Chen Director $4,423,948 18 Mar 2026
Nathan L. Mata Chief Scientific Officer $3,142,374 18 Mar 2026
Ita Lu Director 18 Mar 2026
John Michael Longo Director 18 Mar 2026
Xiao-Hui Chen Director 18 Mar 2026
Gary Clark Biddle Director 18 Mar 2026

Recent Insider Transactions by Companies or Individuals for BELITE BIO, INC

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Hendrik Peter Scholl BLTE Ordinary Share 0 35,000 18 Mar 2026 By Bioptima Ltd.
Nathan L. Mata BLTE Ordinary Share 0 16,666 18 Mar 2026 Direct
Nathan L. Mata BLTE American depositary share 0 16,666 18 Mar 2026 Direct
Hao-Yuan Chuang BLTE Ordinary Share 0 195,264 18 Mar 2026 Direct
Hao-Yuan Chuang BLTE American depositary share 0 100,000 18 Mar 2026 Direct
Xiao-Hui Chen BLTE American depositary share 0 400 18 Mar 2026 Direct
Yu-Hsin Lin BLTE Ordinary Share 0 172,949 18 Mar 2026 Direct
Yu-Hsin Lin BLTE American depositary share 0 180,134 18 Mar 2026 Direct
Wan-Shan Chen BLTE Ordinary Share 0 23,463 18 Mar 2026 Direct
Wan-Shan Chen BLTE American depositary share 0 10,196 18 Mar 2026 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.